Medical Devices includes a session from a regulatory expert on how companies can align their research between regions.

In the ongoing study (NCT06700538), Arrowhead’s candidate, called ARO-INHBE, plus Zepbound, doubled weight loss and tripled ...

Neumora Therapeutics’ oral Alzheimer’s disease agitation drug has shown benefit, reducing agitation, in a Phase Ib trial.

While obexelimab failed to best Uplizna in terms of efficacy, Zenas will still file for the drug’s approval in IgG4-RD.

MetaVia will now be investigating the candidate at two different titration levels in 16-week trials for obesity.

The decision to end the trial was based on an interim analysis that showed a numerically lower favourable response rate and a numerically higher mortality rate in the opelconazole arm. Image credit: ...

GSK said that the drug met its primary endpoint, with more patients achieving functional cure with bepirovirsen plus standard of care compared to standard of care alone. Image credit: Magda Wygralak / ...

MSD aims to enrol around 675 patients worldwide. Credit: Jo Panuwat D / Shutterstock.com. Merck & Co (MSD) has commenced the KANDLELIT-007 Phase III trial to assess calderasib (MK-1084), with Keytruda ...

Johnson & Johnson’s Imaavy (nipocalimab) met its primary and secondary trial endpoints in the Phase IIb JASMINE study in systemic lupus erythematosus (SLE). Image credit: StanislavSukhin via ...

Patients reported clinically meaningful improvements in quality of life and itch. Credit: Hriana / Shutterstock.com. Alumis has announced positive top line data from its Phase III ONWARD1 and ONWARD2 ...

All participants will receive an implantable loop recorder for continuous cardiac rhythm monitoring. Credit: MAD.vertise / Shutterstock.com. Acesion Pharma has commenced enrolment for its Phase II ...

Secondary endpoints of the trial include changes in body weight and fasting blood glucose. Credit: superbeststock / Shutterstock.com. Ascletis Pharma has received investigational new drug (IND) ...